Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability and Pharmacokinetics of a Single Intravenous Administration of SP16-a SERPIN-like, Small Peptide Agonist of the Low Density Lipoprotein-like Receptor 1-in Healthy Individuals

Trial Profile

Safety, Tolerability and Pharmacokinetics of a Single Intravenous Administration of SP16-a SERPIN-like, Small Peptide Agonist of the Low Density Lipoprotein-like Receptor 1-in Healthy Individuals

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs SP-16 (Primary)
  • Indications Diabetes mellitus; Inflammation; Myocardial infarction; Myocardial reperfusion injury
  • Focus Adverse reactions
  • Sponsors Serpin Pharma
  • Most Recent Events

    • 13 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 2 Feb 2019.
    • 13 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 06 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top